Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18976941 | Method and Composition for an Improved Bioavailability Delivery System | December 2024 | August 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 17993693 | ULTRASOUND-TRIGGERED NANOCARRIERS | November 2022 | June 2025 | Abandon | 31 | 3 | 0 | No | No |
| 17908521 | PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR | August 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17636138 | OPHTHALMIC PHARMACEUTICAL COMPOSITION, PREPARATION METHODS AND USES OF THE SAME | July 2022 | February 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17792834 | MEDICINAL COMPOSITIONS FOR CARBON DIOXIDE BASED METERED DOSE INHALERS | July 2022 | August 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17841672 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS AS CARRIERS OF CANNABINOIDS IN STANDARDIZED PRECISION-METERED DOSAGE FORMS | June 2022 | February 2026 | Abandon | 44 | 2 | 0 | No | No |
| 17779702 | MUPS TABLET COMPRISING RIBOFLAVIN | May 2022 | April 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17776481 | NANOPARTICLES FOR MEDICAL AND DIAGNOSITC APPLICATIONS | May 2022 | November 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17741462 | ANTIMICROBIAL NANO-SURFACTANT AND METHODS | May 2022 | February 2026 | Allow | 46 | 0 | 1 | Yes | No |
| 17765386 | SOY PROTEINS FOR PREPARATION OF GELS, FIBERS AND FILMS | March 2022 | March 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17762175 | Polymeric micelle, methods of production and uses thereof | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17689380 | PACKAGING SOLUTIONS | March 2022 | December 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17637374 | A METHOD FOR OBTAINING ION-EXCHANGE POLYMERIC HYDROGELS FOR EYE TREATMENT AND HYDROGEL LENSES THEREOF | February 2022 | June 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17651670 | PEGLOTICASE FOR TREATMENT OF GOUT IN RENAL TRANSPLANT RECIPIENTS | February 2022 | April 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17635667 | Contoured Dressing For Tissue Therapy | February 2022 | November 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17632567 | HERBICIDAL COMBINATION | February 2022 | March 2026 | Allow | 49 | 4 | 0 | Yes | Yes |
| 17631330 | COSMETIC COMPOSITION IN THE FORM OF A COMPACT, IMPACT-RESISTANT POWDER | January 2022 | March 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17628474 | COLOURING EFFECT PIGMENTS AND PRODUCTION THEREOF | January 2022 | October 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17625331 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | January 2022 | September 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17624151 | A WATER-IN-OIL EMULSION WITH EMOLLIENT AND METHODS OF USING THE SAME | December 2021 | October 2025 | Abandon | 46 | 2 | 0 | Yes | Yes |
| 17623459 | CITRIC ACID COATED WOUND DRESSING COMPOSITIONS AND METHODS OF MANUFACTURE | December 2021 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17622732 | CROSS-LINKED HYALURONIC ACID HYDROGELS COMPRISING PROTEINS | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17622001 | COMPOSITION AND METHODS FOR PARASITE CONTROL | December 2021 | October 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17621103 | OIL-IN-WATER EMULSION GEL COMPOSITION | December 2021 | December 2025 | Allow | 48 | 3 | 0 | No | No |
| 17620391 | NANOPARTICLES COMPRISING QUINONE W METHIDES AND COMPOSITIONS FOR USE | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17618662 | DELAYED AND SUSTAINED DELIVERY OF ANTICANCER DRUGS | December 2021 | November 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17617785 | WATER-ACTIVATED MUCOADHESIVE COMPOSITIONS AND METHODS OF DELIVERING BIOLOGICALLY ACTIVE SUBSTANCES | December 2021 | March 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17614955 | NANOTUBES IN POROUS PARTICLES | November 2021 | March 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17612115 | FUNCTIONALIZED FULLERENE GEL TUMOR TREATMENT | November 2021 | August 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17611583 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR | November 2021 | January 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17610965 | UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | November 2021 | December 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17610254 | Improved Lyophilized Formulations Involving Hyaluronic Acid and Plasmatic Proteins, and Uses Thereof | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17603299 | SPRAY-DRIED FORMULATION OF A PYRIDAZINONE TRPC5 INHIBITOR | October 2021 | November 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17601262 | POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAME | October 2021 | October 2025 | Abandon | 48 | 2 | 0 | Yes | No |
| 17601317 | OIL-IN-WATER TYPE EMULSIFICATION COMPOSITION CONTAINING UV WAVELENGTH CONVERSION SUBSTANCE | October 2021 | December 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17593932 | COSMETIC USE OF AMYLOSE-RICH STARCH AS FILM-FORMING AGENT WITH BARRIER AND FIXATIVE EFFECTS | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17599444 | OIL-IN-WATER EMULSION COSMETIC | September 2021 | July 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17598344 | MULTICOMPONENT THERMOPLASTIC PRODUCT | September 2021 | December 2025 | Abandon | 50 | 2 | 0 | No | Yes |
| 17442523 | SLEEP AID TRANSDERMAL PATCH AND ITS PROCESS OF PREPARATION | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17441404 | IMPLANT WITH INTRINSIC ANTIMICROBIAL EFFICACY, AND METHOD FOR THE PRODUCTION THEREOF | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17440605 | NON-AQUEOUS DISPERSION, PREPARATION METHOD THEREFOR, AND COSMETIC COMPOSITION COMPRISING SAME | September 2021 | March 2026 | Allow | 54 | 3 | 0 | Yes | No |
| 17440017 | MEDICAL DEVICE AND PROCESS OF PREPARING A MEDICAL DEVICE | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17439938 | COATING-SECURING AGENT | September 2021 | November 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17439353 | COMPOSITE MICROCAPSULES | September 2021 | May 2025 | Allow | 44 | 2 | 0 | No | No |
| 17472954 | METHOD FOR TREATING CANCER WITH KIDNEY PROTECTION | September 2021 | December 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17437998 | CELL ENCAPSULATION DEVICES AND METHODS OF USING SAME | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17472173 | COMPOSITION, LIPID PARTICLE MANUFACTURING KIT, SUBSTANCE DELIVERY METHOD, AND DETECTION METHOD | September 2021 | November 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17412388 | MICRONEEDLE ARRAY AND METHOD OF PRODUCING MICRONEEDLE ARRAY | August 2021 | May 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17433039 | PARTICULATE AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE MATERIAL | August 2021 | May 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17310689 | SUSTAINED-RELEASE LIPID PREFORMULATION AND PHARMACEUTICAL COMPOSITION FOR SUSTAINED-RELEASE INJECTION IN FORM OF LIPID SOLUTION CONTAINING SAME | August 2021 | January 2025 | Allow | 41 | 2 | 0 | No | No |
| 17430021 | Materials and Methods for Enhanced Treatment and Prevention of Biofilms | August 2021 | November 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17422574 | AGRICULTURAL CHEMICAL PREPARATION CONTAINING DIFENOCONAZOLE, AND METHOD FOR STABILIZING SAID AGRICULTURAL CHEMICAL PREPARATION | July 2021 | August 2025 | Allow | 49 | 3 | 0 | No | No |
| 17309943 | A LIQUID AGRICULTURAL ADJUVANT | July 2021 | February 2026 | Allow | 55 | 3 | 0 | Yes | No |
| 17417320 | METHOD OF CONTROLLING WEEDS | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17413910 | MICROEMULSION COMPOSITIONS OF TOPRAMEZONE | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17413933 | HERBICIDE COMPOSITION AND APPLICATION THEREOF | June 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17296878 | A HERBAL MEDICINE COMPOSITION FOR TREATMENT OF DENGUE AND THEIR PRODUCTION | May 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17288184 | ABSORBABLE IMPLANTABLE DEVICE | April 2021 | August 2025 | Allow | 52 | 2 | 0 | No | No |
| 17276866 | Microbicide Ammonium-Imidazolium Oligomers and Their Anti-Fungal Compositions | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17266227 | IMPLANTABLE BIOMATERIAL, AND METHOD OF MANUFACTURING THEREOF | February 2021 | November 2025 | Allow | 57 | 2 | 0 | Yes | No |
| 17053131 | METHODS OF APPLYING ONE OR MORE CERTAIN HETEROARYL-1,2,4-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS TO CONTROL DAMAGE ON PLANTS, PROPAGATION MATERIAL THEREOF, AND PLANT DERIVED PRODUCTS | November 2020 | July 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16982366 | PEST REPELLENT COMPOSITION | September 2020 | July 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17015266 | HERBICIDE FORMULATION CONTAINING GLUFOSINATE, SOLID HERBICIDE FORMULATION CONTAINING GLYPHOSATE, AND, USE OF HERBICIDE FORMULATION | September 2020 | June 2025 | Abandon | 57 | 3 | 0 | No | No |
| 16718226 | USE OF AN EXTRACT OF PART OF A ROCKET PLANT FOR STIMULATING THE DEFENSES OF PLANTS AND TREES AND ASSOCIATED COMPOSITION AND METHOD | December 2019 | September 2025 | Allow | 60 | 6 | 2 | No | No |
| 16493783 | ANTIMICROBIAL POLYMER COATING COMPOSITION AND ANTIMICROBIAL POLYMER FILM | September 2019 | March 2026 | Allow | 60 | 9 | 1 | Yes | No |
| 16518310 | LOW VOLATILITY HERBICIDAL COMPOSITIONS | July 2019 | March 2025 | Allow | 60 | 9 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOATENG, AFUA BAMFOAA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BOATENG, AFUA BAMFOAA works in Art Unit 1617 and has examined 47 patent applications in our dataset. With an allowance rate of 42.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner BOATENG, AFUA BAMFOAA's allowance rate of 42.6% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOATENG, AFUA BAMFOAA receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BOATENG, AFUA BAMFOAA is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +68.1% benefit to allowance rate for applications examined by BOATENG, AFUA BAMFOAA. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 34.6% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 11.1% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.